Literature DB >> 22728491

A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate.

Yukihiro Wada1, Hiroaki Ogata, Shiho Misawa, Akira Shimada, Eriko Kinugasa.   

Abstract

Extra-gastrointestinal stromal tumors (EGISTs) are rare. We describe a 69-year-old man with a 9-year history of hemodialysis. This patient was diagnosed as having peritoneal tumors measuring over 10 cm in length. Histologically, the tumors were composed of monomorphic spindle cells. The number of mitotic figures was 5 per 50 high-power fields. Immunohistochemical analysis revealed strong positivity for c-KIT and MIB-1. He was treated with imatinib mesylate with no recurrences 20 months later. We present this first case of EGIST in a hemodialysis patient in which imatinib mesylate had a favorable outcome and also discuss the rarity of this case.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728491     DOI: 10.2169/internalmedicine.51.6709

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis.

Authors:  Ryota Niikura; Takako Serizawa; Atsuo Yamada; Shuntaro Yoshida; Mariko Tanaka; Yoshihiro Hirata; Kazuhiko Koike
Journal:  Case Rep Gastroenterol       Date:  2016-05-19

2.  The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.

Authors:  Yasuhiro Taniguchi; Naoto Takahashi; Masatomo Miura; Chikara Hirase; Sanae Sueda; Jorge Luis Espinoza; Shinya Rai; Shoko Nakayama; Kentaro Serizawa; Takahiro Kumode; Yosaku Watatani; Yasuyoshi Morita; Hirokazu Tanaka; Itaru Matsumura
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.